The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.405%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 38.00
MIG1 Live PriceLast checked at -
Maven Income and Growth VCT is an Investment Trust

To achieve long term capital appreciation and generate maintainable levels of income for shareholders through investing in small and medium sized unlisted and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

6 Jul 2023 13:06

RNS Number : 2305F
Maven Income & Growth VCT PLC
06 July 2023
 

 

Maven Income and Growth VCT PLC

 

Result of Annual General Meeting

 

At the Annual General Meeting of the Company held at Kintyre House, 205 West George Street, Glasgow, G2 2LW at 12.00 noon on Thursday 6 July 2023, all of the Resolutions put to the Meeting were passed.

 

At the record date for the Annual General Meeting, being 4 July 2023, the total number of voting rights in the Company stood at 148,939,237 and the total shares in issue were 148,939,237. The Company advises that, for the Annual General Meeting, valid proxy appointments were made in respect of 7,094,849 shares and that the number of proxy votes lodged for each Resolution were as follows:

 

 

Resolutions

For

Discretion

Against

Withheld

Total

1

To receive the Directors' Report and audited Financial Statements

6,719,648

354,970

20,231

0

7,094,849

2

To approve the Directors' Remuneration Report

6,080,633

357,970

575,506

80,740

7,094,849

3

To approve the Directors' Remuneration Policy

5,942,540

357,970

704,353

89,986

7,094,849

4

To approve the payment of a final dividend

 

6,734,144

340,474

20,231

0

7,094,849

5

To re-elect John Pocock as a Director

 

6,555,402

375,334

129,708

34,405

7,094,849

6

To re-elect Alison Fielding as a Director

 

6,679,479

364,970

15,995

34,405

7,094,849

7

To re-elect Andrew Harrington as a Director

 

6,550,286

443,274

66,884

34,405

7,094,849

8

To re-elect Arthur MacMillan as a Director

 

6,518,558

376,289

165,597

34,405

7,094,849

9

To appoint Johnston Carmichael LLP as Auditor

6,694,155

373,289

0

27,405

7,094,849

10

To authorise the Directors to fix the remuneration of the Auditor

6,593,675

426,957

53,815

20,402

7,094,849

11

To renew the Company's authority to allot shares

6,178,350

412,461

481,879

22,159

7,094,849

12

To authorise the Directors to disapply pre-emption rights

6,029,455

427,461

615,774

22,159

7,094,849

13

To renew the Company's authority to purchase its own shares

6,672,361

372,653

47,907

1,928

7,094,849

14

To amend the minimum notice period for a general meeting

6,403,354

383,289

306,654

1,552

7,094,849

A vote withheld is not a vote in law and any such votes have not been included in the votes for or against the respective Resolutions. The voting figures will be available to view at: mavencp.com/migvct.

 

Passing of Resolutions under Special Business

Copies of Resolutions passed under Special Business have been submitted to the National Storage Mechanism and will shortly be available for inspection at: fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Secretary

6 July 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSSFFEMEDSESW
Date   Source Headline
26th Apr 20241:33 pmRNSUnaudited NAV & Proposed Final Dividend
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:47 pmRNSIssue of Equity
27th Mar 202410:34 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
21st Mar 20243:55 pmRNSStatement re Offer for Subscription
20th Mar 20243:44 pmRNSUnaudited Net Asset Value
8th Feb 202410:27 amRNSDirector/PDMR Shareholding
8th Feb 202410:26 amRNSDirector/PDMR Shareholding
8th Feb 202410:08 amRNSIssue of Equity
30th Jan 20245:09 pmRNSTransaction in Own Shares
17th Jan 20249:59 amRNSDirector/PDMR Shareholding
17th Jan 20249:57 amRNSIssue of Equity
15th Jan 20244:25 pmRNSUnaudited Net Value Asset
1st Dec 20239:39 amRNSIssue of Equity
24th Nov 202312:04 pmRNSStatement re Dividend Investment Scheme
9th Nov 20233:35 pmRNSResult of General Meeting
19th Oct 20234:51 pmRNSTransaction in Own Shares
18th Oct 20233:54 pmRNSHalf-year Report
13th Oct 20234:56 pmRNSPublication of a Prospectus
5th Oct 20234:39 pmRNSNet Asset Value and Interim Dividend
20th Jul 20234:32 pmRNSTransaction in Own Shares
14th Jul 20239:26 amRNSIssue of Equity
7th Jul 20234:17 pmRNSStatement re Dividend Investment Scheme
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.